We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84M
AUM Growth
-$31.4M
Cap. Flow
-$24.4M
Cap. Flow %
-29.07%
Top 10 Hldgs %
66.01%
Holding
53
New
14
Increased
7
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$5.79M
2
PFE icon
Pfizer
PFE
+$5.13M
3
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
4
LEGN icon
Legend Biotech
LEGN
+$3.26M
5
CAPR icon
Capricor Therapeutics
CAPR
+$2.58M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$8.55M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$6.66M
3
GPCR icon
Structure Therapeutics
GPCR
+$5.88M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$5.84M
5
ZLAB icon
Zai Lab
ZLAB
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZURA icon
51
Zura Bio
ZURA
$518M
– –
-186,943
Closed -$467K
CLYM
52
Climb Bio
CLYM
$727M
– –
-98,160
Closed -$177K
ONC
53
BeOne Medicines Ltd
ONC
$32.4B
– –
-6,365
Closed -$1.18M
1 2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Superstring Capital Management held 53 positions worth $84M, down 27% from $115M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Superstring Capital Management withdrew a net $24.4M in Q1 2025, closing 19 positions and reducing 9 holdings. Its most notable exit was NovoCure, an estimated $8.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Verona Pharma worth $6.15M.

  • Superstring Capital Management's largest Q1 2025 buy was Verona Pharma: 96,821 shares worth $6.15M.
  • Superstring Capital Management added most to Legend Biotech in Q1 2025, an estimated $3.26M increase.
  • Superstring Capital Management's biggest Q1 2025 reduction was Oric Pharmaceuticals, cutting an estimated $6.66M.
  • Superstring Capital Management fully exited NovoCure in Q1 2025, selling an estimated $8.55M.
  • Superstring Capital Management's ten largest holdings make up 66% of its $84M portfolio in Q1 2025.
  • Superstring Capital Management opened 14 new positions and closed 19 in Q1 2025.
  • Superstring Capital Management's portfolio value fell 27% quarter-over-quarter to $84M.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.